Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best mid cap growth stocks to invest in now. Earlier on June 4, Sarepta Therapeutics announced that the US FDA has granted Platform Technology ...
CDMO Andelyn Biosciences says that it has manufactured a viral vector with its AAV Curator ® Platform for the Nationwide Children’s Hospital’s Cellular Therapy and Cancer Immunology Program. The Adeno ...
Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...
The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy candidate SRP-9003 for limb-girdle muscular dystrophy type 2E/R4 (LGMD2E/R4), ...
Advanced Gene Therapy Development Solutions: A Comprehensive Platform for Next-Generation Therapeutic Innovation: The landscape of gene therapy has evolved dramatically over the past decade, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the ...
Partnership accelerates AGC Biologics' leadership in the AAV market, applying its BravoAAV™ platform to complex gene therapies for inherited blindness MILAN--(BUSINESS WIRE)-- On the heels of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback